iRadimed (NASDAQ:IRMD - Get Free Report) is projected to announce its Q3 2025 results before the market opens on Thursday, October 30th. Analysts expect the company to announce earnings of $0.43 per share and revenue of $20.50 million for the quarter. Investors can check the company's upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Thursday, October 30, 2025 at 11:00 AM ET.
iRadimed Stock Up 2.8%
iRadimed stock opened at $77.58 on Thursday. The firm has a market cap of $986.82 million, a price-to-earnings ratio of 47.89 and a beta of 1.02. iRadimed has a 52 week low of $46.86 and a 52 week high of $78.38. The business's 50-day moving average price is $72.10 and its 200 day moving average price is $62.27.
iRadimed Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Thursday, August 28th. Shareholders of record on Monday, August 18th were given a dividend of $0.17 per share. The ex-dividend date was Monday, August 18th. This represents a $0.68 dividend on an annualized basis and a yield of 0.9%. iRadimed's dividend payout ratio is currently 41.98%.
Wall Street Analysts Forecast Growth
A number of equities analysts have issued reports on IRMD shares. Weiss Ratings reiterated a "buy (b-)" rating on shares of iRadimed in a research report on Wednesday, October 8th. Wall Street Zen upgraded iRadimed from a "buy" rating to a "strong-buy" rating in a research report on Saturday, October 18th. Two investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $72.00.
Check Out Our Latest Research Report on IRMD
Insider Activity at iRadimed
In other news, CEO Roger E. Susi sold 5,000 shares of the firm's stock in a transaction that occurred on Tuesday, October 21st. The stock was sold at an average price of $74.82, for a total value of $374,100.00. Following the transaction, the chief executive officer owned 2,332,500 shares in the company, valued at $174,517,650. This trade represents a 0.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Monty K. Allen sold 1,102 shares of iRadimed stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $69.10, for a total value of $76,148.20. Following the transaction, the director owned 19,898 shares in the company, valued at approximately $1,374,951.80. The trade was a 5.25% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 31,102 shares of company stock worth $2,235,398. Company insiders own 36.80% of the company's stock.
Hedge Funds Weigh In On iRadimed
A number of institutional investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. lifted its position in iRadimed by 1.1% during the first quarter. Goldman Sachs Group Inc. now owns 169,387 shares of the medical equipment provider's stock worth $8,889,000 after buying an additional 1,821 shares in the last quarter. Qube Research & Technologies Ltd lifted its position in iRadimed by 2.0% during the second quarter. Qube Research & Technologies Ltd now owns 48,537 shares of the medical equipment provider's stock worth $2,902,000 after buying an additional 964 shares in the last quarter. Raymond James Financial Inc. lifted its position in iRadimed by 4.7% during the second quarter. Raymond James Financial Inc. now owns 42,952 shares of the medical equipment provider's stock worth $2,568,000 after buying an additional 1,918 shares in the last quarter. Lazard Asset Management LLC lifted its position in iRadimed by 5.2% during the second quarter. Lazard Asset Management LLC now owns 41,110 shares of the medical equipment provider's stock worth $2,457,000 after buying an additional 2,036 shares in the last quarter. Finally, Royal Bank of Canada increased its stake in iRadimed by 14.7% during the first quarter. Royal Bank of Canada now owns 25,782 shares of the medical equipment provider's stock worth $1,354,000 after acquiring an additional 3,307 shares during the last quarter. Hedge funds and other institutional investors own 92.34% of the company's stock.
About iRadimed
(
Get Free Report)
IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider iRadimed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iRadimed wasn't on the list.
While iRadimed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
